Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05394350
Title A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0103) Miami Florida 33136 United States Details
Laura and Isaac Perlmutter Cancer Center ( Site 0102) New York New York 10016 United States Details
South Texas Accelerated Research Therapeutics (START) ( Site 0101) San Antonio Texas 78229 United States Details
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201) Toronto Ontario M5G 2M9 Canada Details
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0 Quebec G1J 1Z4 Canada Details
Rigshospitalet ( Site 0500) Copenhagen Hovedstaden 2100 Denmark Details
Herlev and Gentofte Hospital ( Site 0501) Copenhagen Hovedstaden 2730 Denmark Details
Odense Universitetshospital ( Site 0502) Odense Syddanmark 5000 Denmark Details
Rambam Health Care Campus-Oncology Division ( Site 0300) Haifa 3109601 Israel Details
Hadassah Medical Center ( Site 0302) Jerusalem 9112001 Israel Details
Kantonsspital Graubünden-Medizin ( Site 0402) Chur Grisons 7000 Switzerland Details
Cantonal Hospital St.Gallen ( Site 0403) st.Gallen Sankt Gallen 9007 Switzerland Details
Ospedale Regionale Bellinzona e Valli ( Site 0400) Bellinzona Ticino 6500 Switzerland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field